Second-line treatment of postmenopausal women with advanced breast carcinoma

Ruth E. Board; Emma J. Dean; Claire Mitchell; Andrew M. Wardley

doi:10.1586/14737140.6.4.613

Second-line treatment of postmenopausal women with advanced breast carcinoma

Ruth E. Board, Emma J. Dean, Claire Mitchell, Andrew M. Wardley

Research output: Contribution to journal › Article › peer-review

Abstract

Breast cancer is the most prevalent cancer in women and, currently, there is no standard of care for the treatment of metastatic disease. Treatment options are based on a number of tumor- and patient-related factors. This review explores some of these options, including the use of hormonal manipulation in the treatment of hormone-positive disease, current chemotherapy options and the use of targeted therapies, such as trastuzumab. © 2006 Future Drugs Ltd.

Original language	English
Pages (from-to)	613-624
Number of pages	11
Journal	Expert Review of Anticancer Therapy
Volume	6
Issue number	4
DOIs	https://doi.org/10.1586/14737140.6.4.613
Publication status	Published - Apr 2006

Keywords

Aromatase inhibitors
Breast cancer
Chemotherapy
Postmenopausal
Tamoxifen
Trastuzumab
Treatment

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1586/14737140.6.4.613

http://www.future-drugs.com/doi/full/10.1586/14737140.6.4.613

Cite this

@article{c77a4550940b45f28607d60a9a1cff90,

title = "Second-line treatment of postmenopausal women with advanced breast carcinoma",

abstract = "Breast cancer is the most prevalent cancer in women and, currently, there is no standard of care for the treatment of metastatic disease. Treatment options are based on a number of tumor- and patient-related factors. This review explores some of these options, including the use of hormonal manipulation in the treatment of hormone-positive disease, current chemotherapy options and the use of targeted therapies, such as trastuzumab. {\textcopyright} 2006 Future Drugs Ltd.",

keywords = "Aromatase inhibitors, Breast cancer, Chemotherapy, Postmenopausal, Tamoxifen, Trastuzumab, Treatment",

author = "Board, \{Ruth E.\} and Dean, \{Emma J.\} and Claire Mitchell and Wardley, \{Andrew M.\}",

year = "2006",

month = apr,

doi = "10.1586/14737140.6.4.613",

language = "English",

volume = "6",

pages = "613--624",

journal = "Expert Review of Anticancer Therapy",

issn = "1473-7140",

publisher = "Taylor \& Francis",

number = "4",

}

TY - JOUR

T1 - Second-line treatment of postmenopausal women with advanced breast carcinoma

AU - Board, Ruth E.

AU - Dean, Emma J.

AU - Mitchell, Claire

AU - Wardley, Andrew M.

PY - 2006/4

Y1 - 2006/4

N2 - Breast cancer is the most prevalent cancer in women and, currently, there is no standard of care for the treatment of metastatic disease. Treatment options are based on a number of tumor- and patient-related factors. This review explores some of these options, including the use of hormonal manipulation in the treatment of hormone-positive disease, current chemotherapy options and the use of targeted therapies, such as trastuzumab. © 2006 Future Drugs Ltd.

AB - Breast cancer is the most prevalent cancer in women and, currently, there is no standard of care for the treatment of metastatic disease. Treatment options are based on a number of tumor- and patient-related factors. This review explores some of these options, including the use of hormonal manipulation in the treatment of hormone-positive disease, current chemotherapy options and the use of targeted therapies, such as trastuzumab. © 2006 Future Drugs Ltd.

KW - Aromatase inhibitors

KW - Breast cancer

KW - Chemotherapy

KW - Postmenopausal

KW - Tamoxifen

KW - Trastuzumab

KW - Treatment

UR - https://www.scopus.com/pages/publications/33746296242

U2 - 10.1586/14737140.6.4.613

DO - 10.1586/14737140.6.4.613

M3 - Article

C2 - 16613548

SN - 1473-7140

VL - 6

SP - 613

EP - 624

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

IS - 4

ER -

Second-line treatment of postmenopausal women with advanced breast carcinoma

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this